{"componentChunkName":"component---src-templates-study-details-page-js","path":"/en/study/102881","result":{"data":{"studyNotFoundJson":{"title":"Study not found","content":{"childMarkdownRemark":{"html":"<p>If you entered a web address please check it was correct.</p>\n<p>You can also try <a href=\"/en/studies\">Search Page</a> to find the study you are looking for.</p>"}}},"trialDetailsJson":{"title":"Details Page","returnSearch":"Back to search results","description":"Study Description","identifier":"ViiV Study ID","clinicalID":"Clinicaltrials.gov Identifier","EudraCtID":"EudraCT Number","resultsAvailable":"Has Results Available Below","docAvailable":"Has Results Document Available","studyOverview":"Study Overview","overviewSection":{"conditionsDisplay":"Medical Conditions","product":"Product","collaborators":"Collaborators","dates":"Date","studyType":"Type","phase":"Phase","gender":"Gender","age":"Age","acceptVolunteers":"Accepts Healthy Volunteers"},"studyDocuments":"Study Documents","noDocuments":"No documents available","studyDocumentsAdditionalText":"If you wish to request for Full Study Report, please contact - ","studyDocumentsAdditionalEmail":"GSKClinicalSupportHD@gsk.com","isReleased":{"firstPart":"This study has Protocol and Result summary on ClinicalTrial.gov. Click","secondPart":"to learn more.","linkText":"here"},"mapLocations":"Locations","centralContact":"Central Contact","centralPhone":"Central Contact Phone","centralEmail":"Central Contact Email","mapSection":{"site":"GSK Investigational Site","condition":"Condition","id":"Study ID","city":"City","state":"State","zip":"Zip","country":"Country"},"studyDesign":"Study Design","designSection":{"purpose":"Primary Purpose","allocation":"Allocation","study_design":"Study Design","study_classification":"Study Classification","masking":"Masking","masked_subject":"Masked Subject","masked_caregiver":"Masked Caregiver","masked_investigator":"Masked Investigator","masked_assessor":"Masked Assessor","primary_outcomes":"Primary Outcomes","secondary_outcomes":"Secondary Outcomes","arms":"Arms","interventions":"Interventions","keyword":"Keyword","inclusionTitle":"Inclusion Criteria","exclusionTitle":"Exclusion Criteria","criteriaText":"Inclusion/Exclusion Criteria","criteria_button":"Click to view inclusion/exclusion criteria","enrollment":"Enrollment","clinicalPublications":"Clinical Publications"},"popoversText":{"studyId":{"childMarkdownRemark":{"html":"<p>A unique number for a study given by ViiV.</p>"}},"ctGov":{"childMarkdownRemark":{"html":"<p>This number identifies the study on the US clinicaltrials.gov register. Click this link to go to the entry for this study on Clinicaltrials.gov where you will be able to see protocol and results summaries where available.</p>"}},"eudraCT":{"childMarkdownRemark":{"html":"<p>This number identifies the study on the EU clinicaltrials.eu register. Click this link to go to the entry for this study on clinicaltrials.eu where you will be able to see protocol and results summaries where available.</p>"}}}},"site":{"siteMetadata":{"siteUrl":"https://www.viiv-studyregister.com"}},"studyDetails":{"nct_number":"NCT00104429","ctis_id":"","HasResults":"false","IpdAccessCriteria":"","IpdDescription":"","IpdInfoTypeAnalyticCode":"","IpdInfoTypeIcf":"","IpdInfoTypeCsr":"","IpdInfoTypeProtocol":"","IpdInfoTypeSap":"","IpdTimeFrame":"","IpdUrl":"","IsFlexibleTrial":false,"IsReleasedToCtGov":"true","MaskingInfo":{"masked_assessor":"false","masked_caregiver":"false","masked_investigator":"false","masked_subject":"false","masking_description":"","no_masking":""},"PatientLevelData":"false","SharingIpd":"","acronym":"","allocation":"Randomized","arm_groups":[],"assignment":"Parallel Assignment","brief_summary":"This study is a 96-week study designed to evaluate the safety and efficacy of GW873140 in combination with Combivir in HIV infected, untreated subjects.","brief_summary_OneLinkTx":"","brief_title_OneLinkTx":"","brief_title":"GW873140 In Combination With Combivir In HIV Infected Subjects","conditions":[{"DisplayValue":"Human Immunodeficiency Virus (HIV)","DisplayValue_OneLinkTx":"","InternalValue":"CON_HIV","LookupValue":"Infection, Human Immunodeficiency Virus I","LookupValue_OneLinkTx":""}],"created_date":"09/15/2018 17:39:57","criteria":"Inclusion criteria: - HIV infected subjects. - Females must be of either non-childbearing age, or have a negative pregnancy test. - All subjects participating in this study should be counseled on the practice of safe sex using a proven double barrier method of contraception throughout the study. - Screening lab result of plasma HIV-1 RNA greater than or equal to 10,000 copies/mL and CD4 cell count greater than or equal to 100 cells/mm3. - Have CC Chemokine Receptor5-tropic (R5-tropic) virus based on viral tropism test at screening visit. - Have no drug resistance mutations in HIV-1 Reverse Transcriptase based on resistance test at screening visit. - Be treatment-naive, defined as less than or equal to 2 weeks of treatment with a protease inhibitor (PI) or a nucleoside reverse transcriptase inhibitor/nucleotide reverse transcriptase inhibitor (NRTI/ NtRTI), or less than or equal to 7 days of therapy with a non-nucleoside reverse transcriptase inhibitor (NNRTI). - Prior treatment with any entry inhibitor, attachment inhibitor, or fusion inhibitor (experimental or approved) is not allowed. - Be able to understand and follow with protocol requirements, instructions and protocol-stated restrictions. - Signed and dated written informed consent prior to study entry. Exclusion criteria: - Detection of any CXC Receptor4-tropic (X4-tropic) virus, based on viral tropism test at screening. - Any drug resistance mutations in HIV-1 Reverse Transcriptase based on resistance test at screening visit. - Active Class C AIDS-defining illness. - Laboratory abnormalities at screen. - Significant blood loss prior to study start. - Pregnant or breastfeeding women. - Additional qualifying criteria to be determined by the physician.","detailed_description":"A Phase IIb, 96 week, randomized, partially double-blinded, multicenter, parallel group, repeat dose study to evaluate the safety, tolerability, pharmacokinetics and antiviral effect of GW873140 in combination with Combivir (lamivudine and zidovudine) upon selected immunological and virological markers of HIV-1 infection in antiretroviral therapy naive adults","display_gender":"Both","display_gender_internal":"GENDER_ALL","display_phase":"Phase 2","display_phase_internal":"PHASE_2","display_status":"Other","display_status_internal":"RECSTATUS_OTHER","endpoint":"","enrollment":"125","exclusion":"","gender":"Both","gender_based":"","gender_description":"","healthy_volunteers":"No","id":"f7f8c683-2d00-5e9c-9d22-b7b140a5a154","internal":{"content":null,"contentDigest":"ec0543fac973d0c19592a2fe2b6938e5","description":null,"fieldOwners":null,"mediaType":null,"ignoreType":null,"owner":"default-site-plugin","type":"studyDetails"},"inclusion":"Inclusion criteria: - HIV infected subjects. - Females must be of either non-childbearing age, or have a negative pregnancy test. - All subjects participating in this study should be counseled on the practice of safe sex using a proven double barrier method of contraception throughout the study. - Screening lab result of plasma HIV-1 RNA greater than or equal to 10,000 copies/mL and CD4 cell count greater than or equal to 100 cells/mm3. - Have CC Chemokine Receptor5-tropic (R5-tropic) virus based on viral tropism test at screening visit. - Have no drug resistance mutations in HIV-1 Reverse Transcriptase based on resistance test at screening visit. - Be treatment-naive, defined as less than or equal to 2 weeks of treatment with a protease inhibitor (PI) or a nucleoside reverse transcriptase inhibitor/nucleotide reverse transcriptase inhibitor (NRTI/ NtRTI), or less than or equal to 7 days of therapy with a non-nucleoside reverse transcriptase inhibitor (NNRTI). - Prior treatment with any entry inhibitor, attachment inhibitor, or fusion inhibitor (experimental or approved) is not allowed. - Be able to understand and follow with protocol requirements, instructions and protocol-stated restrictions. - Signed and dated written informed consent prior to study entry. Exclusion criteria: - Detection of any CXC Receptor4-tropic (X4-tropic) virus, based on viral tropism test at screening. - Any drug resistance mutations in HIV-1 Reverse Transcriptase based on resistance test at screening visit. - Active Class C AIDS-defining illness. - Laboratory abnormalities at screen. - Significant blood loss prior to study start. - Pregnant or breastfeeding women. - Additional qualifying criteria to be determined by the physician.","interventions":[{"arm_group_label":"","intervention_description":"","intervention_name":"GW873140","intervention_type":"Drug"},{"arm_group_label":"","intervention_description":"","intervention_name":"Combivir","intervention_type":"Drug"}],"interventional_subtype":"Treatment","is_fda_regulated":null,"is_high_value":false,"is_ind_study":true,"keywords":["HIV infections","therapy naive"],"last_follow_up_date":"01/01/2006 00:00:00","links":[],"locations":[{"City":"Wuerzburg","Latitude":"49.8158268","CountryDisplay":"Germany","Longitude":"9.9102608","Name":"GSK Investigational Site","StateDisplay":"Bayern","PostalCode":"97080","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Lisboa","Latitude":"38.7222524","CountryDisplay":"Portugal","Longitude":"-9.1393366","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"1169-100","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Tampa","Latitude":"27.9717504","CountryDisplay":"United States","Longitude":"-82.4915194","Name":"GSK Investigational Site","StateDisplay":"Florida","PostalCode":"33607","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Dallas","Latitude":"32.7962048","CountryDisplay":"United States","Longitude":"-96.7694752","Name":"GSK Investigational Site","StateDisplay":"Texas","PostalCode":"75246","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Bakersfield","Latitude":"35.3873576","CountryDisplay":"United States","Longitude":"-119.0168962","Name":"GSK Investigational Site","StateDisplay":"California","PostalCode":"93301","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Ottawa","Latitude":"45.4227425","CountryDisplay":"Canada","Longitude":"-75.6824915","Name":"GSK Investigational Site","StateDisplay":"Ontario","PostalCode":"K1N 6N5","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Dallas","Latitude":"32.7556954","CountryDisplay":"United States","Longitude":"-96.7654595","Name":"GSK Investigational Site","StateDisplay":"Texas","PostalCode":"75215","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Milano","Latitude":"45.5000627","CountryDisplay":"Italy","Longitude":"9.2273552","Name":"GSK Investigational Site","StateDisplay":"Lombardia","PostalCode":"20127","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Hannover","Latitude":"52.3763832","CountryDisplay":"Germany","Longitude":"9.8026933","Name":"GSK Investigational Site","StateDisplay":"Niedersachsen","PostalCode":"30625","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Madrid","Latitude":"40.4765501","CountryDisplay":"Spain","Longitude":"-3.7003632","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"28029","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Brescia","Latitude":"45.5203846","CountryDisplay":"Italy","Longitude":"10.1857711","Name":"GSK Investigational Site","StateDisplay":"Lombardia","PostalCode":"25125","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Minneapolis","Latitude":"44.9605503","CountryDisplay":"United States","Longitude":"-93.2616717","Name":"GSK Investigational Site","StateDisplay":"Minnesota","PostalCode":"55404","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Washington","Latitude":"38.9191485","CountryDisplay":"United States","Longitude":"-77.0362967","Name":"GSK Investigational Site","StateDisplay":"District of Columbia","PostalCode":"20009","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Milano","Latitude":"45.5145841","CountryDisplay":"Italy","Longitude":"9.1358629","Name":"GSK Investigational Site","StateDisplay":"Lombardia","PostalCode":"20157","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Levallois-Perret","Latitude":"48.893217","CountryDisplay":"France","Longitude":"2.287864","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"92300","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Miami","Latitude":"25.7870967","CountryDisplay":"United States","Longitude":"-80.2042436","Name":"GSK Investigational Site","StateDisplay":"Florida","PostalCode":"33136","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"San Francisco","Latitude":"37.7561438","CountryDisplay":"United States","Longitude":"-122.4325682","Name":"GSK Investigational Site","StateDisplay":"California","PostalCode":"94114","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Rochester","Latitude":"43.1581207","CountryDisplay":"United States","Longitude":"-77.6063541","Name":"GSK Investigational Site","StateDisplay":"New York","PostalCode":"14604","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Los Angeles","Latitude":"34.070264","CountryDisplay":"United States","Longitude":"-118.4440562","Name":"GSK Investigational Site","StateDisplay":"California","PostalCode":"90095","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Las Vegas","Latitude":"36.1462673","CountryDisplay":"United States","Longitude":"-115.1829873","Name":"GSK Investigational Site","StateDisplay":"Nevada","PostalCode":"89102","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Philadelphia","Latitude":"39.9559288","CountryDisplay":"United States","Longitude":"-75.1574567","Name":"GSK Investigational Site","StateDisplay":"Pennsylvania","PostalCode":"19107","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Conyers","Latitude":"33.6392536","CountryDisplay":"United States","Longitude":"-83.985008","Name":"GSK Investigational Site","StateDisplay":"Georgia","PostalCode":"30013","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Coimbra","Latitude":"40.2191523","CountryDisplay":"Portugal","Longitude":"-8.4098211","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"3000-075","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Orlando","Latitude":"28.5747416","CountryDisplay":"United States","Longitude":"-81.3949264","Name":"GSK Investigational Site","StateDisplay":"Florida","PostalCode":"32804","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"London","Latitude":"51.5073509","CountryDisplay":"United Kingdom","Longitude":"-0.1277583","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"EC1 7BE","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Tarzana","Latitude":"34.1494848","CountryDisplay":"United States","Longitude":"-118.5506158","Name":"GSK Investigational Site","StateDisplay":"California","PostalCode":"30342","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Bruxelles","Latitude":"50.8427501","CountryDisplay":"Belgium","Longitude":"4.3515499","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"1000","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"New York","Latitude":"40.7097781","CountryDisplay":"United States","Longitude":"-74.0098271","Name":"GSK Investigational Site","StateDisplay":"New York","PostalCode":"10008","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Lyon Cedex 02","Latitude":"45.686106","CountryDisplay":"France","Longitude":"5.045359","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"69288","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Frankfurt","Latitude":"50.1109221","CountryDisplay":"Germany","Longitude":"8.6821267","Name":"GSK Investigational Site","StateDisplay":"Hessen","PostalCode":"60590","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Vero Beach","Latitude":"27.6445079","CountryDisplay":"United States","Longitude":"-80.4048306","Name":"GSK Investigational Site","StateDisplay":"Florida","PostalCode":"32960","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Chicago","Latitude":"41.8816606","CountryDisplay":"United States","Longitude":"-87.6926257","Name":"GSK Investigational Site","StateDisplay":"Illinois","PostalCode":"60612","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Newark","Latitude":"40.7301363","CountryDisplay":"United States","Longitude":"-74.1742268","Name":"GSK Investigational Site","StateDisplay":"New Jersey","PostalCode":"7102","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Brighton","Latitude":"50.8187517","CountryDisplay":"United Kingdom","Longitude":"-0.1201139","Name":"GSK Investigational Site","StateDisplay":"Sussex East","PostalCode":"BN2 1ES","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Denver","Latitude":"39.7558119","CountryDisplay":"United States","Longitude":"-104.9680914","Name":"GSK Investigational Site","StateDisplay":"Colorado","PostalCode":"80205","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Toronto","Latitude":"43.7215696","CountryDisplay":"Canada","Longitude":"-79.3768256","Name":"GSK Investigational Site","StateDisplay":"Ontario","PostalCode":"M4N 3M5","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Dallas","Latitude":"32.7457134","CountryDisplay":"United States","Longitude":"-96.8458204","Name":"GSK Investigational Site","StateDisplay":"Texas","PostalCode":"75208","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Stanford","Latitude":"37.4135757","CountryDisplay":"United States","Longitude":"-122.1689284","Name":"GSK Investigational Site","StateDisplay":"California","PostalCode":"94305","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Boston","Latitude":"42.3652917","CountryDisplay":"United States","Longitude":"-71.0646337","Name":"GSK Investigational Site","StateDisplay":"Massachusetts","PostalCode":"02114","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Portland","Latitude":"45.5478224","CountryDisplay":"United States","Longitude":"-122.7288206","Name":"GSK Investigational Site","StateDisplay":"Oregon","PostalCode":"97210","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Montreal","Latitude":"45.5179048","CountryDisplay":"Canada","Longitude":"-73.558878","Name":"GSK Investigational Site","StateDisplay":"Québec","PostalCode":"H2L 4P9","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Porto","Latitude":"41.1826169","CountryDisplay":"Portugal","Longitude":"-8.6003756","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"4200-319","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"London","Latitude":"51.4847527","CountryDisplay":"United Kingdom","Longitude":"-0.1836283","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"SW10 9TH","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Montreal","Latitude":"45.5152072","CountryDisplay":"Canada","Longitude":"-73.5562284","Name":"GSK Investigational Site","StateDisplay":"Québec","PostalCode":"H2L 5B1","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Beverly Hills","Latitude":"34.1030032","CountryDisplay":"United States","Longitude":"-118.4104684","Name":"GSK Investigational Site","StateDisplay":"California","PostalCode":"90210","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Paris","Latitude":"48.891305","CountryDisplay":"France","Longitude":"2.3529867","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"75018","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Los Angeles","Latitude":"34.0238187","CountryDisplay":"United States","Longitude":"-118.153228","Name":"GSK Investigational Site","StateDisplay":"California","PostalCode":"90022","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Providence","Latitude":"41.8380136","CountryDisplay":"United States","Longitude":"-71.4358733","Name":"GSK Investigational Site","StateDisplay":"Rhode Island","PostalCode":"02908","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Nantes","Latitude":"47.196147","CountryDisplay":"France","Longitude":"-1.537269","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"44093","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Birmingham","Latitude":"52.4366501","CountryDisplay":"United Kingdom","Longitude":"-1.9375135","Name":"GSK Investigational Site","StateDisplay":"Warwickshire","PostalCode":"B29 6JD","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Manchester","Latitude":"53.5191895","CountryDisplay":"United Kingdom","Longitude":"-2.2276047","Name":"GSK Investigational Site","StateDisplay":"Lancashire","PostalCode":"M8 5RB","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"}],"masking":"Open Label","maximum_age_raw":"N/A N/A","maximum_age":"N/A","minimum_age":"18","minimum_age_raw":"18 years","modified_date":"10/01/2018 22:18:09","number_of_arms":"","observational_design":{"biospecimen_description":"","biospecimen_retention":"","number_of_groups":"","observational_study_design":"","patient_registry":"","target_duration_quantity":"","target_duration_units":"","timing":""},"official_title":"A PhaseIIb, 96 week, randomised, partially double-blinded, multicentre, parallel group, repeat dose study to evaluate the safety, tolerability, PK and antiviral effect of GW873140 in combination with COMBIVIR (lamivudine and zidovudine) upon selected immunological and virological markers of HIV-1 infection in antiretroviral therapy naive adults","org_study_id":"102881","overall_contact":{"email":"GSKClinicalSupportHD@gsk.com","last_name":"Call Center","phone":"877-379-3718"},"overall_status":"Terminated","oversight_info":{"exported_from_us":"","fda_regulated_device":"","fda_regulated_drug":"","ped_postmarket_surv":"","has_dmc":null,"post_prior_to_approval":"","regulatory_authorities":[""]},"phase":"2","primary_compl_date":"01/01/2006 00:00:00","primary_outcomes":[{"outcome_description":"","outcome_measure":"Proportion of subjects with viral loads <400 copies/mL remaining on randomized treatment through Week 12","outcome_time_frame":"","outcome_safety_issue":null}],"product_name":"","product_name_OneLinkTx":"","secondary_ids":[],"secondary_outcomes":[{"outcome_description":"","outcome_measure":"- Comparison of safety and tolerability of different dosage regimens of GW873140 plus Combivir to standard of care regimen. - Assessment of drug resistance over time. - Co-receptor tropism following virological failure.","outcome_time_frame":"","outcome_safety_issue":null}],"sponsors":{"investigator_affiliation":"","investigator_username":"None","lead_sponsor":"ViiV Healthcare","collaborators":[]},"start_date":"01/01/2005 00:00:00","study_type":"Interventional","therapeutic_area":"Infectious Diseases","citations":[],"is_section_801":null}},"pageContext":{"studyId":"102881"}},"staticQueryHashes":["162689979","3332233851","3729204765","3769354840","399703114"]}